Copyright ©2012 Alkermes, Inc. All rights reserved.
When starting a new patient on VIVITROL, assist them in getting their VIVITROL treatment. Enroll your patients in the TouchpointsSM Support Services Program. Touchpoints' experienced team of reimbursement specialists and case coordinators work closely with your office staff and the specialty pharmacy to:
TouchpointsSM Support Services is designed to comply with federal privacy regulations.
If you have additional questions about the TouchpointsSM Support Services program, please call 1-800-VIVITROL (1-800-848-4876).
92% of patients utilizing the program have no out-of-pocket expense for VIVITROL
The VIVITROL Value Program was created to help patients with prescription or VIVITROL treatment costs. Eligible patients* may qualify for $0 co-pay, and can print their own unique co-pay card for immediate savings on co-pay costs.
*Eligibility for Alkermes-Sponsored Co-pay Assistance: This offer is valid up to a maximum of $500 per month, and only for prescriptions for FDA-approved indications. You must be at least 18 years old. If you are receiving benefits from Medicaid, Medicare, or TRICARE® — or another federal or state healthcare program, including any state medical or pharmaceutical assistance program — you are not eligible for this offer. Void where prohibited by law, taxed or restricted. Alkermes, Inc. reserves the right to rescind, revoke or amend these offers without notice.
Help protect your VIVITROL patients in case they need emergency treatment. Give them the VIVITROL pain management card. This card will help alert emergency personnel that your patient is being treated with VIVITROL. Download a Pain Management Card
Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses.
Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects.
The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. VIVITROL does not appear to be a hepatotoxin at the recommended doses.
Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of VIVITROL should be discontinued in the event of symptoms and/or signs of acute hepatitis.
Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support. Opioid-dependent patients, including those being treated for alcohol dependence, must be opioid-free at the time of initial VIVITROL administration. VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. Patients should not be actively drinking at the time of initial VIVITROL administration. VIVITROL is also indicated for the prevention of relapse to opioid dependence, following opioid detoxification.
VIVITROL is contraindicated in patients with acute hepatitis or liver failure, patients receiving opioid analgesics, patients with current physiologic opioid dependence, patients in acute opioid withdrawal, any individual who has failed the naloxone challenge test or has a positive urine screen for opioids, and in patients who have previously exhibited hypersensitivity to naltrexone, polylactide-co-glycolide (PLG), carboxymethylcellulose or any other components of the diluent.
VIVITROL is administered as an intramuscular (IM) gluteal injection. Inadvertent subcutaneous injection of VIVITROL may increase the likelihood of severe injection site reactions. VIVITROL must be injected using one of the customized needles provided in the carton. Because needle length may not be adequate due to body habitus, each patient should be assessed prior to each injection to assure that needle length is adequate for IM administration. VIVITROL injections may be followed by pain, tenderness, induration, swelling, erythema, bruising or pruritus; however, in some cases injection site reactions may be very severe. Injection site reactions not improving may require prompt medical attention, including in some cases surgical intervention. Consider the diagnosis of eosinophilic pneumonia if patients develop progressive dyspnea and hypoxemia. Patients should be warned of the risk of hypersensitivity reactions, including anaphylaxis. Opioid-dependent patients including those being treated for alcohol dependence, must be opioid-free for a minimum of 7-10 days before VIVITROL treatment. Attempts to overcome opioid blockade due to VIVITROL may result in a fatal overdose. After opioid detoxification, patients are likely to have reduced tolerance to opioids. Use of lower doses of opioids after VIVITROL is discontinued, at the end of a dosing interval or after missing a dose could result in life threatening opioid intoxication. Alcohol- and opioid-dependent patients, including those taking VIVITROL, should be monitored for the development of depression or suicidal thoughts. As with any IM injection, VIVITROL should be administered with caution to patients with thrombocytopenia or any coagulation disorder. In an emergency situation in patients receiving VIVITROL, suggestions for pain management include regional analgesia or use of non-opioid analgesics. Patients requiring reversal of the VIVITROL blockade for pain management should be monitored by appropriately trained personnel in a setting equipped for cardiopulmonary resuscitation. Caution is recommended in administering VIVITROL to patients with moderate to severe renal impairment.
The adverse events seen most frequently in association with VIVITROL therapy for alcohol dependence include nausea, vomiting, injection site reactions (including induration, pruritus, nodules and swelling), muscle cramps, dizziness or syncope, somnolence or sedation, anorexia, decreased appetite or other appetite disorders. The adverse events seen most frequently in association with VIVITROL in opioid-dependent patients include hepatic enzyme abnormalities, injection site pain, nasopharyngitis, insomnia, and toothache.
Share this site with a friend or colleague by entering their
e-mail address below and clicking the Send button.
All Fields Required
Friend's e-mail address is required; please enter it here. Please enter your friend's e-mail address in the correct format, ie, email@example.com
This field is required; please enter your friend's name.
This field is required; please enter your e-mail address. Please enter your e-mail address in the correct format, ie, firstname.lastname@example.org
This field is required; please enter your name.
|There was an error while trying to send this email. Please try again.|